Evidence map›Paper›PMID 38938563›Full record

ArticleFrontiers in immunology2024

BMAL2 promotes eCIRP-induced macrophage endotoxin tolerance.

Mian Zhou, Monowar Aziz, Jingsong Li, Alok Jha, Gaifeng Ma, Atsushi Murao, Ping Wang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Circadian clock and cancer.Military Medical Research · 2026
    Review
  3. Article
  4. Review
  5. Recent Advances of Trained immunity in Macrophages.International journal of biological sciences · 2025
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mian ZhouCenter for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.
Monowar Aziz *Center for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.
Jingsong LiCenter for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.
Alok JhaCenter for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.
Gaifeng MaCenter for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.
Atsushi MuraoCenter for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.
Ping Wang *Center for Immunology and Inflammation, The Feinstein Institutes for Medical Research, Manhasset, NY, United States.

Funding

Novel Approaches to Maintaining Organ Function in SepsisR35GM118337 · NIGMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI PING WANG · 2016 to 2026
$5.2M
NIGMS NIH HHS R35 GM118337
6 · The paper itself

Abstract

Background: The disruption of the circadian clock is associated with inflammatory and immunological disorders. BMAL2, a critical circadian protein, forms a dimer with CLOCK, activating transcription. Extracellular cold-inducible RNA-binding protein (eCIRP), released during sepsis, can induce macrophage endotoxin tolerance. We hypothesized that eCIRP induces BMAL2 expression and promotes macrophage endotoxin tolerance through triggering receptor expressed on myeloid cells-1 (TREM-1). Methods: C57BL/6 wild-type (WT) male mice were subjected to sepsis by cecal ligation and puncture (CLP). Serum levels of eCIRP 20 h post-CLP were assessed by ELISA. Peritoneal macrophages (PerM) were treated with recombinant mouse (rm) CIRP (eCIRP) at various doses for 24 h. The cells were then stimulated with LPS for 5 h. The levels of TNF-α and IL-6 in the culture supernatants were assessed by ELISA. PerM were treated with eCIRP for 24 h, and the expression of PD-L1, IL-10, STAT3, TREM-1 and circadian genes such as BMAL2, CRY1, and PER2 was assessed by qPCR. Effect of TREM-1 on eCIRP-induced PerM endotoxin tolerance and PD-L1, IL-10, and STAT3 expression was determined by qPCR using PerM from TREM-1 Results: Serum levels of eCIRP were increased in septic mice compared to sham mice. Macrophages pre-treated with eCIRP exhibited reduced TNFα and IL-6 release upon LPS challenge, indicating macrophage endotoxin tolerance. Additionally, eCIRP increased the expression of PD-L1, IL-10, and STAT3, markers of immune tolerance. Interestingly, TREM-1 deficiency reversed eCIRP-induced macrophage endotoxin tolerance and significantly decreased PD-L1, IL-10, and STAT3 expression. PCR array screening of circadian clock genes in peritoneal macrophages treated with eCIRP revealed the elevated expression of BMAL2, CRY1, and PER2. In eCIRP-treated macrophages, TREM-1 deficiency prevented the upregulation of these circadian genes. In macrophages, inducible BMAL2 expression correlated with increased PD-L1 expression. In septic human patients, blood monocytes exhibited increased expression of BMAL2 and PD-L1 in comparison to healthy subjects. Computational modeling and BIAcore assay identified a putative binding region of BMAL2 in the PD-L1 promoter, suggesting BMAL2 positively regulates PD-L1 expression in macrophages. Conclusion: eCIRP upregulates BMAL2 expression via TREM-1, leading to macrophage endotoxin tolerance in sepsis. Targeting eCIRP to maintain circadian rhythm may correct endotoxin tolerance and enhance host resistance to bacterial infection.

Indexed as

RNA-Binding ProteinsSepsisAnimalsARNTL Transcription FactorsDisease Models, AnimalEndotoxinsHumansImmune ToleranceLipopolysaccharidesMacrophagesMacrophages, PeritonealMaleMiceMice, Inbred C57BLMice, KnockoutTriggering Receptor Expressed on Myeloid Cells-1Arntl2 protein, mouseARNTL Transcription FactorsBMAL2 protein, humanCIRBP protein, humanCirbp protein, mouseEndotoxinsLipopolysaccharidesRNA-Binding ProteinsTREM1 protein, mouseTriggering Receptor Expressed on Myeloid Cells-1BMAL2circadianeCIRPimmune tolerancemacrophagesPD-L1

Identifiers

PMID38938563
PMCPMC11208452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.